BRAF and metastatic melanoma: The fidelity of cancer-driving mutations, pharmacological response and development of resistance observed between PDXCs and PDXs suggests that PDXCs alone may constitute a suitable precision medicine platform for discovering novel drug combinations to target BRAF inhibitor- resistant metastatic melanoma.